5 December 2018 - NICE is unable to make a recommendation about the use of two medicines in the NHS because no evidence submission was received.

NICE is unable to make a recommendation on the use of:

• Decitabine for untreated acute myeloid leukaemia (Janssen)
  
• Denosumab for the prevention of skeletal-related events in multiple myeloma (Amgen)
  

NICE will review this decision if Janssen/Amgen decides to make a submission.

Read NICE guidance for decitabine

Read NICE guidance for denosumab